More on ISIS

- Summary
- Chart
- Profile
- Historical


- Earnings
- Ratings
- Holders


Income Statement
Balance Sheet
Cash Flow Statement


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

ISIS Income Statement

Click line-items for a historical chart and %
Research and development revenue under collaborative agreements 19.55M
Licensing and royalty revenue 8.61M
Total revenue 28.16M
Research and development
General and administrative 4.38M
Total operating expenses 57.83M
Loss from operations -29.67M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
Investment income 657K
Interest expense -4.94M
Gain (loss) on investments, net 397K
Loss before income tax expense
Income tax expense
Net loss
Basic net loss (in dollars per share)
Diluted net loss (in dollars per share)
Shares used in computing basic net loss per share (in shares)
Shares used in computing diluted net loss per share (in shares)